Pharmacokinetics of CTLA4Ig fusion protein in healthy volunteers and patients with rheumatoid arthritis
about
Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Orencia in Rheumatoid Arthritis Registry.Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and an inadequate response to conventional or biologic disease-modifying antirheumatic drugs.Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosisCTLA4-Ig in B7-1-positive diabetic and non-diabetic kidney disease.Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis.Generation and preclinical characterization of a Fc-optimized GITR-Ig fusion protein for induction of NK cell reactivity against leukemia.Modeling pharmacokinetics/pharmacodynamics of abatacept and disease progression in collagen-induced arthritic rats: a population approach.A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding.Model-based determination of abatacept exposure in support of the recommended dose for Japanese rheumatoid arthritis patients.Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody.Porcine CTLA4-Ig prolong islet xenografts in rats by downregulating the direct pathway of T-cell activation.Relative efficiency of porcine and human cytotoxic T-lymphocyte antigen 4 immunoglobulin in inhibiting human CD4+ T-cell responses co-stimulated by porcine and human B7 moleculesAn Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemiaTolerability and efficacy of abatacept in Japanese patients with rheumatoid arthritis: a phase I study
P2860
Q31152756-0E465261-4F5E-4BA7-9FC8-0BFD7B188817Q34172853-45784A75-2A2E-477C-9635-A8666ABA4D41Q35135825-B92F5057-6522-4410-BD35-A1E075C0D22CQ38593433-518F0D49-D468-419D-B493-7FFD23B962CAQ38617817-DB34E46A-6D72-4FB0-B862-942FCE0BA8F1Q39591125-92AFF1C2-906D-4E2D-8519-58376207BC87Q42416736-9F1DB137-ABB8-44B8-82A4-9FD5BA939854Q45299093-ADAD62AC-612B-4C0C-BBDB-1F1B293C802FQ46699062-E69BFAEC-0073-486A-8879-9D5EFD1F5D5AQ46866013-EE8840D5-9C1A-4632-87E4-8C36074E0A7DQ53080962-D8A1A726-18AE-4D65-9EFA-4512EC3BB2B3Q56898413-BF3B1AD2-673A-419C-8892-96669A0404F0Q57257115-60E02CB0-8A65-40D9-8278-D0A104496E3CQ58204744-FEBBD75A-8581-4382-9DAC-48BEA6336473
P2860
Pharmacokinetics of CTLA4Ig fusion protein in healthy volunteers and patients with rheumatoid arthritis
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacokinetics of CTLA4Ig fu ...... ents with rheumatoid arthritis
@en
Pharmacokinetics of CTLA4Ig fu ...... nts with rheumatoid arthritis.
@nl
type
label
Pharmacokinetics of CTLA4Ig fu ...... ents with rheumatoid arthritis
@en
Pharmacokinetics of CTLA4Ig fu ...... nts with rheumatoid arthritis.
@nl
prefLabel
Pharmacokinetics of CTLA4Ig fu ...... ents with rheumatoid arthritis
@en
Pharmacokinetics of CTLA4Ig fu ...... nts with rheumatoid arthritis.
@nl
P2093
P2860
P356
P1476
Pharmacokinetics of CTLA4Ig fu ...... ents with rheumatoid arthritis
@en
P2093
Ai-dong Wen
Bi-rong Lin
Wei-zhu Qian
P2860
P2888
P304
P356
10.1038/APS.2009.13
P577
2009-03-01T00:00:00Z
P5875
P6179
1036290918